The collaboration with Scenic Biotech could potentially lead to significant advancements in genetic research for Bristol Myers Squibb, leveraging the innovative Cell-Seq technology. The financial commitment in terms of an upfront payment and potential milestone payments indicates a strong belief in the value of this partnership. This could lead to positive investor sentiment in the short term, as it showcases BMY's proactive approach in enhancing its research capabilities.